

## #12005 SUMMARY

SUMMARY REVIEW EDITING

### SUBMISSION

Authors	dr. Sahrun -, Dr. Laksmi Wulandari, dr., SP.P(K)
Title	MANAGEMENT OF PROGRESSIVE LUNG CANCER PATIENTS AFTER FIRST-LINE EGFR TYROSINE KINASE INHIBITOR THERAPY
Original file	<a href="#">12005-41868-1-SM.DOC</a> 2019-02-21
Supp. files	None
Submitter	Dr. Laksmi Wulandari, dr., SP.P(K)
Date submitted	February 21, 2019 - 01:40 AM
Section	Articles
Editor	FMI Section Editor 2

### STATUS

Status	Archived
Initiated	2019-11-25
Last modified	2019-11-25

### SUBMISSION METADATA

[EDIT METADATA](#)

#### AUTHORS

Name	dr. Sahrun -
Affiliation	Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Airlangga University, Dr. Soetomo General Hospital
Country	Indonesia
Bio Statement	—
Name	Dr. Laksmi Wulandari, dr., SP.P(K)
URL	<a href="https://www.unair.ac.id/site/menu/show/52/lecturer-detail/21-197811072016016101/-isnin-anang-marhana-dr-spp-k-fccp">https://www.unair.ac.id/site/menu/show/52/lecturer-detail/21-197811072016016101/-isnin-anang-marhana-dr-spp-k-fccp</a>
Affiliation	(SCOPUS ID: 52464692000) Pulmonary and Respiratory Medicine, Faculty of Medicine Universitas Airlangga, Dr. Soetomo Hospital, Indonesia
Country	Indonesia
Bio Statement	—
Principal contact for editorial correspondence.	

#### TITLE AND ABSTRACT

Title	MANAGEMENT OF PROGRESSIVE LUNG CANCER PATIENTS AFTER FIRST-LINE EGFR TYROSINE KINASE INHIBITOR THERAPY
Abstract	<b>ABSTRACT</b>

Various tyrosine kinase inhibitor (TKI) drugs have been widely used as therapy for cancer that has EGFR mutations, or abnormal EGFR activation. However, patients who have a mutation in the gene that activates EGFR only benefit from EGFR-TKI therapy for less than one year, because after that resistance occurs. In the management of patients according to NCCN 2017, patients who experience progress after receiving TKI as the first-line therapy must undergo an examination to identify the presence of T790M mutation. If the T790M mutation is positive, the choice of therapy that needs to be provided is the third generation (Osimertinib). Many recent studies have proved the significance of the effectiveness and response of Osimertinib therapy in lung cancer with EGFR T790M mutation. We reported the management of a pulmonary adenocarcinoma patient with positive EGFR mutation who had received first-line EGFR TKI who had progressive disease and T790M mutation in Dr. Soetomo Hospital. The patient finally received Osimertinib through an Early Access Program with a therapeutic response that improved significantly.

#### INDEXING

Academic discipline and sub-disciplines	—
Keywords	Keywords: tyrosine kinase inhibitor; TKI resistance; T790M mutation; progressive disease; Osimertinib
Language	en

#### ISSN

Printed ISSN

Electronic ISSN

#### Instruction for Author

[How to Submit](#)

[Guidelines for Authors](#)

[Online Submission](#)

[Document Template](#)

[CTA & Author Statement](#)

#### Journal Policy

[Focus and Scope](#)

[Publication Ethics](#)

[Article Processing Charge](#)

[Editorial Team](#)

[Peer Reviewers](#)

[Peer Review Process](#)

[Peer Review Process Flowchart](#)

[Open Access Statement](#)

[Plagiarism Check](#)

[Archiving](#)

[Copyright](#)

[Repository Policy](#)

[Contact](#)

[Old Website](#)

#### Journal Standing

Scopus<sup>®</sup>

[Reference Manager](#)

MENDELEY

[Plagiarism Checker](#)

turnitin

[External Links](#)



[In Collaboration with](#)

SUPPORTING AGENCIES

Agencies —

REFERENCES

References REFERENCES

Arief N (2009). Kegawatdaruratan Paru, Departemen Pulmonologi Dan Ilmu Kedokteran Respirasi FKUI RS PERSAHABATAN, Universitas Indonesia

Blom JW, Doggen CJ, Osanto S, et al (2005). Malignancies, prothrombotic mutations, and the risk of venous thrombosis. *JAMA* 293, p 715-722. Available from <https://www.ncbi.nlm.nih.gov/pubmed/15701913>. Accessed 09 13, 2018

Brzezniak C, Oronsky B, Carter CA, et al (2017). Superior Vena Cava Syndrome in a Patient with Small-Cell Lung Cancer: A Case Report. *Case Rep Oncol* 10, p 252-257

Carson JL, Kelley MA, Duff A, et al (1992). The clinical course of pulmonary embolism. *N Engl J Med* 326, p 1240-1245. Available from <https://www.ncbi.nlm.nih.gov/pubmed/1560799>. Accessed 09 11, 2018

Ciardiello F, Tortora G (2008). EGFR Antagonists in Cancer Treatment. *N Engl J Med* 358, p 1160-1174

David SE, Douglas EW, Dara LA, et al (2017). Non-Small Cell Lung Cancer, Version 5, Clinical Practice Guidelines in Oncology. *J National Comprehensive Cancer Network (NCCN)* 15(4), p 504-535

Ettinger DS, Akerley W, Bepler G, et al (2010). Non - Small Cell Lung Cancer Clinical Practice Guidelines in Oncology. *Natl Compr Cancer Netw* 8(7), p 740-801

Falanga A (2009). The incidence and risk of venous thromboembolism associated with cancer and nonsurgical cancer treatment. *Cancer Invest* 27(1), p 105-115. Available from <https://www.ncbi.nlm.nih.gov/pubmed/19160098>. Accessed 09 14, 2018

Greene FL, Page DL, Fleming ID, et al (2002). *Cancer Survival Analysis*. In : *AJJ Cancer Staging handbook*, 6th ed, New York, Springer, p 15-25

Huang L, Fu L (2015). Mechanisms of resistance to EGFR tyrosine kinase inhibitors. *Acta Pharmaceutica Sinica B* 5(5), p 390-401. Available from <https://core.ac.uk/download/pdf/82702660.pdf>. Accessed 09 12, 2018

Jemal A, Bray F, Center MM, et al (2003). Global cancer statistics. *A Cancer Journal Clinicians* 61, p 69-90

Kosasih, Alvin, Susanto AD, et al 2008. Diagnosis Dan Tatalaksana Kegawatdaruratan Paru Dalam Praktek Sehari-hari, Jakarta, Sagung Seto

Lee AY (2005). Management of thrombosis in cancer: primary prevention and secondary prophylaxis. *Br J Haematol* 128, p 291-302. Available from <https://www.ncbi.nlm.nih.gov/pubmed/15667530>. Accessed 09 10, 2018

Mok TS, Wu YL, Thongprasert S, et al (2009). Gefitinib or carboplatinpaclitaxel in pulmonary Adenokarsinoma. *N Engl J Med* 361, p 947-57

Nordstrom M, Lindblad B, Bergqvist D, et al (1992). A prospective study of the incidence of deep-vein thrombosis within a defined urban population. *J Intern Med* 232(2), p 155-160. Available from <https://www.ncbi.nlm.nih.gov/pubmed/1506812>. Accessed 09 14, 2018

Parkin DM, Bray F, Ferlay J, et al (2002). Global cancer statistics 2002. *A Cancer Journal Clinicians* 55(2), p 74-108

Rosell R, Moran T, Queralt C, et al (2009). Screening for epidermal growth factor receptor mutations in lung cancer. *N Engl J Med* 361, p 958-67

Sequist LV, Waltman BA, Dias-Santagata D, et al (2011). Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. *Sci Transl Med* 3, p 75ra26

Shinagare AB, Guo M, Hatabu H, et al (2011). Incidence of pulmonary embolism in oncologic outpatients at a tertiary cancer center. *Cancer* 117, p 3860-6. Available from <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3131455/>. Accessed 09 11, 2018

Socinski MA, Villaruz LC, Ross J (2016). Understanding Mechanisms of Resistance in the Epithelial Growth Factor Receptor in Non-Small Cell Lung Cancer and the Role of Biopsy at Progression. *Oncologist* 21, p 1-9

Sorensen HT, Mellemkjaer L, Olsen JH, et al (2000). Prognosis of cancers associated with venous thromboembolism. *N Engl J Med* 343, p 1846-50. Available from <https://www.ncbi.nlm.nih.gov/pubmed/11117976>. Accessed 09 13, 2018

Thomas A, D'Amico MD, Malcolm M, et al (2004). EGF receptor gene mutation are common in lung cancer from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. *Proceedings of the National Academy of Science* 101(36), USA, p 13306 - 11

WHO (2004). Histological of the tumor of the lung. In: *Tumor of the lung-WHO classification*

Yang P, Cerhan JR, Vierkan RA, et al (2002). Adenokarsinoma of the Lung Is Strongly Associated with Cigarette Smoking: Further Evidence from a Prospective Study of Women. *American Journal of Epidemiology* 156(12), p 1114-1122

Yun C, Mengwasser KE, Toms A V, et al (2008). The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. *Proc Natl Acad Sci USA* 105(6), p 2070-2075. Available from <https://www.ncbi.nlm.nih.gov/pubmed/18227510>. Accessed 09 11, 2018

Indexed By



IKATAN DOKTER INDONESIA SURABAYA

Accreditation Certificate



OPEN JOURNAL SYSTEMS

Journal Help

USER

You are logged in as...

**laksmiwulandari**

- [My Journals](#)
- [My Profile](#)
- [Log Out](#)

AUTHOR

Submissions

- [Active \(0\)](#)
- [Archive \(5\)](#)
- [New Submission](#)

NOTIFICATIONS

- [View \(44 new\)](#)
- [Manage](#)

JOURNAL CONTENT

Search

Search Scope   
 All

Browse

- [By Issue](#)
- [By Author](#)
- [By Title](#)
- [Other Journals](#)

FONT SIZE

INFORMATION

- [For Readers](#)
- [For Authors](#)
- [For Librarians](#)

Visitors

	ID 51,799		PH 800
	US 6,975		AU 723
	IN 1,731		GB 656
	MY 969		TH 571
	JP 849		CA 484

Pageviews: 275,031





This work is licensed under a [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License](https://creativecommons.org/licenses/by-nc-sa/4.0/).

**00232944** [View My Stats](#)



Pusat Pengembangan Jurnal dan Publikasi Ilmiah  
**Universitas Airlangga**  
copyright@2017 Template PPJPI